Transcriptional Dependencies in Diffuse Intrinsic Pontine Glioma

Cancer Cell. 2017 May 8;31(5):635-652.e6. doi: 10.1016/j.ccell.2017.03.011. Epub 2017 Apr 20.

Abstract

Diffuse intrinsic pontine glioma (DIPG) is a fatal pediatric cancer with limited therapeutic options. The majority of cases of DIPG exhibit a mutation in histone-3 (H3K27M) that results in oncogenic transcriptional aberrancies. We show here that DIPG is vulnerable to transcriptional disruption using bromodomain inhibition or CDK7 blockade. Targeting oncogenic transcription through either of these methods synergizes with HDAC inhibition, and DIPG cells resistant to HDAC inhibitor therapy retain sensitivity to CDK7 blockade. Identification of super-enhancers in DIPG provides insights toward the cell of origin, highlighting oligodendroglial lineage genes, and reveals unexpected mechanisms mediating tumor viability and invasion, including potassium channel function and EPH receptor signaling. The findings presented demonstrate transcriptional vulnerabilities and elucidate previously unknown mechanisms of DIPG pathobiology.

Keywords: BRD4; CDK7; DIPG; EPH; oligodendrocyte precursor cell; potassium channel; super-enhancer.

MeSH terms

  • Animals
  • Antineoplastic Combined Chemotherapy Protocols / pharmacology*
  • Azepines / pharmacology*
  • Brain Stem Neoplasms / drug therapy*
  • Brain Stem Neoplasms / genetics
  • Brain Stem Neoplasms / metabolism
  • Brain Stem Neoplasms / pathology
  • Cell Cycle Proteins
  • Cell Proliferation / drug effects
  • Chromatin Assembly and Disassembly / drug effects
  • Cyclin-Dependent Kinase-Activating Kinase
  • Cyclin-Dependent Kinases / antagonists & inhibitors
  • Cyclin-Dependent Kinases / genetics
  • Cyclin-Dependent Kinases / metabolism
  • Dose-Response Relationship, Drug
  • Drug Resistance, Neoplasm
  • Drug Synergism
  • Female
  • Gene Expression Regulation, Neoplastic / drug effects*
  • Glioma / drug therapy*
  • Glioma / genetics
  • Glioma / metabolism
  • Glioma / pathology
  • Histone Deacetylase Inhibitors / pharmacology*
  • Histones / genetics
  • Histones / metabolism
  • Humans
  • Hydroxamic Acids / pharmacology*
  • Indoles / pharmacology*
  • Male
  • Mice, Inbred NOD
  • Mice, SCID
  • Mutation
  • Nuclear Proteins / antagonists & inhibitors
  • Nuclear Proteins / genetics
  • Nuclear Proteins / metabolism
  • Panobinostat
  • Phenylenediamines / pharmacology*
  • Primary Cell Culture
  • Protein Kinase Inhibitors / pharmacology*
  • Pyrimidines / pharmacology*
  • RNA Interference
  • Receptors, Eph Family / genetics
  • Receptors, Eph Family / metabolism
  • Signal Transduction / drug effects
  • Time Factors
  • Transcription Factors / antagonists & inhibitors
  • Transcription Factors / genetics
  • Transcription Factors / metabolism
  • Transcription, Genetic / drug effects*
  • Transfection
  • Triazoles / pharmacology*
  • Tumor Cells, Cultured
  • Xenograft Model Antitumor Assays

Substances

  • (+)-JQ1 compound
  • Azepines
  • BRD4 protein, human
  • Cell Cycle Proteins
  • Histone Deacetylase Inhibitors
  • Histones
  • Hydroxamic Acids
  • Indoles
  • Nuclear Proteins
  • Phenylenediamines
  • Protein Kinase Inhibitors
  • Pyrimidines
  • THZ1 compound
  • Transcription Factors
  • Triazoles
  • Panobinostat
  • Receptors, Eph Family
  • Cyclin-Dependent Kinases
  • Cyclin-Dependent Kinase-Activating Kinase